Cargando…

The Therapeutic Potential of CDK4/6 Inhibitors, Novel Cancer Drugs, in Kidney Diseases

Inflammation is a crucial pathological feature in cancers and kidney diseases, playing a significant role in disease progression. Cyclin-dependent kinases CDK4 and CDK6 not only contribute to cell cycle progression but also participate in cell metabolism, immunogenicity and anti-tumor immune respons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Xuan-Bing, Dai, Zhi-Cheng, Zou, Rong, Tang, Ji-Xin, Yao, Cui-Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487876/ https://www.ncbi.nlm.nih.gov/pubmed/37686364 http://dx.doi.org/10.3390/ijms241713558

Ejemplares similares

Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease
por: Dai, Zhi-Cheng, et al.
Publicado: (2023)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
por: Sun, Ran, et al.
Publicado: (2022)

Senescence as a therapeutically relevant response to CDK4/6 inhibitors
por: Wagner, Verena, et al.
Publicado: (2020)

Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer
por: Wu, Yanmei, et al.
Publicado: (2020)

Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib
por: Zhu, Lin, et al.
Publicado: (2022)

Development of CDK inhibitors as cancer therapeutics
por: Lane, D
Publicado: (2005)

Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
por: Li, Zhen, et al.
Publicado: (2020)

Clinicopathologic Features of Acute Kidney Injury Associated With CDK4/6 Inhibitors
por: Gupta, Shruti, et al.
Publicado: (2021)

Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
por: Hanna, Paul E., et al.
Publicado: (2023)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer
por: Saleh, Lubaid, et al.
Publicado: (2021)

CDK7 inhibitors as anticancer drugs
por: Sava, Georgina P., et al.
Publicado: (2020)

A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas
por: Hadjadj, Djihad, et al.
Publicado: (2017)

Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia
por: Bride, Karen L., et al.
Publicado: (2021)

Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer
por: Dang, Fabin, et al.
Publicado: (2021)

CDK 4/6 inhibitors for the treatment of meningioma
por: Young, Jacob S., et al.
Publicado: (2022)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
por: Wu, Xuewei, et al.
Publicado: (2021)

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions
por: Roncato, Rossana, et al.
Publicado: (2020)

Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer
por: Kase, Adam M, et al.
Publicado: (2020)

CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review)
por: Huang, Jinyao, et al.
Publicado: (2022)

A narrative review about CDK4/6 inhibitors in the setting of drug resistance: updates on biomarkers and therapeutic strategies in breast cancer
por: Zhao, Shidi, et al.
Publicado: (2023)

CDK4/6 inhibitor: from quiescence to senescence
por: Yoshida, Akihiro, et al.
Publicado: (2015)

CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
por: Yang, Yilan, et al.
Publicado: (2020)

Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors
por: Sorf, Ales, et al.
Publicado: (2020)

Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067
por: Shen, Shen, et al.
Publicado: (2020)

Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells
por: Buzzetti, Marta, et al.
Publicado: (2021)

Therapeutic potential of CDK11 in cancer
por: Blazek, Dalibor
Publicado: (2023)

MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?
por: Lelliott, Emily J., et al.
Publicado: (2022)

Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
por: Hu, Ye, et al.
Publicado: (2021)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
por: Yang, C, et al.
Publicado: (2017)

Expression of CDK6 in Stomach Cancer and the Effect of CDK4/6 Inhibitor PD-0332991 on the Function of Stomach Cancer Cells
por: Liu, Yu, et al.
Publicado: (2022)

CDK1 serves as a novel therapeutic target for endometrioid endometrial cancer
por: Ying, Xue, et al.
Publicado: (2021)

Unraveling the genomic determinants of response to CDK4/6 inhibitors
por: Litchfield, Lacey M., et al.
Publicado: (2018)

The role of CDK4/6 inhibitors in early breast cancer
por: Gil-Gil, Miguel, et al.
Publicado: (2021)

Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC
por: Zhang, Jinmeng, et al.
Publicado: (2021)

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
por: van Aken, Evert S. M., et al.
Publicado: (2021)

CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
por: Garutti, Mattia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rmjjlchnku41e0dlom65oc3ifr